Produced by the Royal College of Physicians of Edinburgh and Royal College of Physicians and Surgeons of Glasgow

References

  1. Pincus T, Callahan LF, Sale WG et al. Severe functional declines, work disability and increased mortality in seventy five RA patients studied over 9 years. Arthritis Rheum 1984; 27:864–72.
  2. Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the early RA study (ERAS). Ann Rheum Dis 2002; 61(4):335– 40.
  3. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomised controlled trial. Lancet 2004; 363(9410):675–81.
  4. Lipsky PE, van der Heijde DMFM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594–602.
  5. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340(4):253–9.
  6. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364(9430):263–9.
  7. Korpela M, Laasonen L, Hannonen P et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease modifying anti-rheumatic drugs. Arthritis Rheum 2004; 50(7):2072–81.
  8. Maini R, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50(4):1051–65.
  9. Breedveld FC, Emery P, Keystone E et al. Infliximab in early active rheumatoid arthritis. Ann Rheum Dis 2004; 63(2):149–55.
  10. Tsakonas E, Fitzgerald AA, Fitzcharles MA et al. Consequences of delayed therapy with second-line therapy in rheumatoid arthritis: a 3-year follow up on hydroxychloroquine in early rheumatoid arthritis study. J Rheumatol 2000; 27:623–9.